In the trial, Camzyos or placebo was added to the highest tolerated dose of standard therapy. The trial showed that Camzyos improved symptoms in patients, and significantly reduced eligibility for ...

Camzyos (mavacamten), a first-in-class heart disease drug ... It is estimated that there are millions of patients worldwide who could benefit from this therapy.

(RTTNews) - French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with ...

(RTTNews) - GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for GSK5764227, its B7-H3-targeted antibody-drug conjugate (ADC ...